Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction
Open Access
- 1 April 2003
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (4) , 492-496
- https://doi.org/10.1034/j.1600-6143.2003.00074.x
Abstract
Despite the serious direct and indirect deleterious effects caused by cytomegalovirus (CMV), the optimal prophylactic strategy remains unknown. We sought to determine whether combination prophylaxis...Keywords
This publication has 12 references indexed in Scilit:
- Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label studyTransplantation Proceedings, 2001
- LOW RATE OF ACUTE LUNG ALLOGRAFT REJECTION AFTER THE USE OF DACLIZUMAB, AN INTERLEUKIN 2 RECEPTOR ANTIBODYTransplantation, 2001
- Prevention and treatment of cytomegalovirus disease in heart transplant patientsPublished by Elsevier ,2000
- THE SAFETY AND EFFICACY OF A TWO-DOSE DACLIZUMAB (ZENAPAX) INDUCTION THERAPY IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- Influence of anti‐rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipientsClinical Transplantation, 2000
- REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1Transplantation, 1999
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- Sequelae of Cytomegalovirus Pulmonary Infections in Lung Allograft RecipientsAmerican Review of Respiratory Disease, 1992
- Cytomegalovirus infections in heart and heart-lung transplant recipientsJournal of Antimicrobial Chemotherapy, 1989
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987